Background and Objective: Retinoids show promise in the treatment of various (pre)malignancies, including head and neck squamous cell carcinoma (HNSCC). It has been shown that metabolic pathways of retinoids are important in their anticancer effect and that these pathways may change during HNSCC carcinogenesis. We have previously reported that HNSCC cells have a 17-fold greater turnover rate of retinoic acid (RA) than normal oral keratinocytes from noncancer controls, and that the formation of polar metabolites such as 4-oxo-RA and 4-hydroxy-RA is only seen in HNSCC cell lines. We aimed to establish whether this altered retinoid metabolism is an intrinsic characteristic of HNSCC patients. Methods: The normal mucosa of cancer and noncancer patients was the source of keratinocyte cultures. The cells were exposed to RA for various time periods, and the levels of various retinoids were measured in the culture medium and cell pellets with reverse-phase liquid chromatography. Results: Cells from cancer patients were morphologically normal and showed no genetic aberrations (i.e. loss of heterozygosity). The RA turnover rate in normal oral keratinocytes of cancer patients was 15 times higher (p = 0.003) than that in normal oral keratinocytes of noncancer controls, with average turnover rates of 218.6 and 14.8 pmol/mg protein/h, respectively. Specific profiles of RA metabolites were similar. Conclusion: The observed higher RA metabolism in noncancer cells of HNSCC patients suggests that individuals with a relatively high RA turnover have an increased risk of developing HNSCC.

1.
Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer. N Engl J Med 1993;328:184–194.
2.
Harris CC: Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Res 1991;51(18 suppl):5023s–5044s.
3.
Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramore GE, Marcial VA, Davis LW, Cox JD, et al: Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17:449–456.
4.
Snow GB: Follow-up in patients treated for head and neck cancer: How frequent, how thorough and for how long? Eur J Cancer 1992;28:315–316.
5.
Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang ZF, Tobi H, Braakhuis BJ, Snow GB: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:530–535.
6.
Cloos J, Nieuwenhuis EJ, Boomsma DI, Kuik DJ, van der Sterre ML, Arwert F, Snow GB, Braakhuis BJ: Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst 1999;91:1125–1130.
7.
Lotan R: Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980;605:33–91.
8.
De Luca LM: Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991;5:2924–2933.
9.
Wille JJ, Chopra DP: Reversal by retinoids of keratinization induced by benzo(alpha)pyrene in normal hamster tracheal explants: Comparison with the assay involving organ culture of tracheas from vitamin A-deficient hamsters. Cancer Lett 1988;40:235–246.
10.
Lippman SM, Kessler JF, Al Sarraf M, Alberts DS, Itri LM, Mattox D, Von Hoff DD, Loescher L, Meyskens FL: Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: A phase II randomized trial. Invest New Drugs 1988;6:51–56.
11.
Hong WK, Lippman SM, Hittelman WN, Lotan R: Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic. Clin Cancer Res 1995;1:677–686.
12.
Hong WK, Itri LM: Retinoids and human cancer; in Sporn MB, Roberts AB, Goodman DS (eds): The Retinoids. New York, Raven, 1994, pp 597–630.
13.
Xu XC, Clifford JL, Hong WK, Lotan R: Detection of nuclear retinoic acid receptor mRNA in histological tissue sections using nonradioactive in situ hybridization histochemistry. Diagn Mol Pathol 1994;3:122–131.
14.
Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405–1410.
15.
Guo X, Gudas LJ: Metabolism of all-trans-retinol in normal human cell strains and squamous cell carcinoma (SCC) lines from the oral cavity and skin: Reduced esterification of retinol in SCC lines. Cancer Res 1998;58:166–176.
16.
Klaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ: Enhanced turnover of all-trans-retinoic acid and increased formation of polar metabolites in head and neck squamous cell carcinoma cells compared to normal oral keratinocytes. Clin Cancer Res 2001;7:1017–1025.
17.
Klaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ: Considerations for in vitro retinoid experiments: Importance of protein interaction. Biochim Biophys Acta 1999;1427:265–275.
18.
Reid CB, Cloos J, Snow GB, Braakhuis BJ: A simple and reliable technique for culturing of human oral keratinocytes and fibroblasts. Acta Otolaryngol 1997;117:628–633.
19.
Carey TE, Wolf GT, Baker SR, Krause CJ: Cell surface antigen expression and prognosis; in Fee WE, Goephert H, Johns ME, Strong EW, Ward PH (eds): Head and Neck Cancer. Toronto, B.C. Decker, 1990, pp 77–82.
20.
Hermsen MA, Joenje H, Arwert F, Welters MJ, Braakhuis BJ, Bagnay M, Westerveld A, Slater R: Centromeric breakage as a major cause of cytogenetic abnormalities in oral squamous cell carcinoma. Genes Chromosomes Cancer 1996;15:1–9.
21.
Welters MJ, Fichtinger-Schepman AM, Baan RA, Hermsen MA, van der Vijgh WJ, Cloos J, Braakhuis BJ: Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer 1997;71:410–415.
22.
Braakhuis BJ, Jansen G, Noordhuis P, Kegel A, Peters GJ: Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. Biochem Pharmacol 1993;46:2155–2161.
23.
Teerlink T, Copper MP, Klaassen I, Braakhuis BJ: Simultaneous analysis of retinol, all-trans- and 13-cis-retinoic acid and 13-cis-4-oxoretinoic acid in plasma by liquid chromatography using on-column concentration after single-phase fluid extraction. J Chromatogr B Biomed Sci Appl 1997;694:83–92.
24.
Eckhoff C, Nau H: Identification and quantitation of all-trans- and 13-cis-retinoic acid and 13-cis-4-oxoretinoic acid in human plasma. J Lipid Res 1990;31:1445–1454.
25.
Furr HC, Barua AB, Olson JA: Analytical methods; in Sporn MB, Roberts AB, Goodman DS (eds): The Retinoids. New York, Raven, 1994, pp 179–209.
26.
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996;56:2488–2492.
27.
Rigas JR, Miller VA, Zhang ZF, Klimstra DF, Tong WP, Jris MG, Warell RP: Metabolic phenotypes of retinoic acid and the risk of lung cancer. Cancer Res 1996;56:2692–2696.
28.
Lotan R: Retinoids in cancer chemoprevention. FASEB J 1996;10:1031–1039.
29.
Graham S: Epidemiology of retinoids and cancer. J Natl Cancer Inst 1984;73:1423–1428.
30.
Ray WJ, Bain G, Yao M, Gottlieb DI: CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem 1997;272:18702–18708.
31.
White JA, Beckett-Jones B, Guo YD, Dilworth FJ, Bonasoro J, Jones G, Petkovich M: cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J Biol Chem 1997;272:18538–18541.
32.
Buck J, Myc A, Garbe A, Cathomas G: Differences in the action and metabolism between retinol and retinoic acid in B lymphocytes. J Cell Biol 1991;115:851–859.
33.
Hermanek P, Sobin LH: TNM Classification of Malignant Tumours. Berlin, Springer, 1987.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.